Anti‐EGFR antibody‐drug conjugate for triple‐negative breast cancer therapy

Triple‐negative breast cancers (TNBCs) are highly aggressive, metastatic and recurrent. Cytotoxic chemotherapies with limited clinical benefits and severe side effects are the standard therapeutic strategies, but, to date, there is no efficacious targeted therapy. Literature and our data showed that...

Descripción completa

Detalles Bibliográficos
Autores principales: Si, Yingnan, Xu, Yuanxin, Guan, JiaShiung, Chen, Kai, Kim, Seulhee, Yang, Eddy S., Zhou, Lufang, Liu, Xiaoguang Margaret
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7837297/
https://www.ncbi.nlm.nih.gov/pubmed/33531889
http://dx.doi.org/10.1002/elsc.202000027

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7837297/
https://www.ncbi.nlm.nih.gov/pubmed/33531889
http://dx.doi.org/10.1002/elsc.202000027

Ejemplares similares